523 HEMODYNAMIC EFFECTS OF TEZOSENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH CIRRHOSIS von Lebrec, D, Bosch, J, Jalan, R, Dudley, F.J, Jesic, R, Garcia-Pagan, J.C, Mookerjee, R, Moreau, R, van Giersbergen, P.L.M, Kusic-Pajic, A, Dingemanse, J

Volltext

EP42675, a synthetic parenteral dual‐action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs von Gueret, P., Krezel, C., Fuseau, E., Giersbergen, P. L. M., Petitou, M., Neuhart, E.

Volltext

COMT Inhibition by Tolcapone Further Improves Levodopa Pharmacokinetics when Combined with a Dual-Release Formulation of Levodopa/Benserazide von Gasser, U.E., Jorga, K., Crevoisier, C., Hovens, S.E.L., van Giersbergen, P.L.M.

Volltext

Activation by full and partial agonists of M1 to M5 human muscarinic receptors expressed in A9L or CHO cells von Richards, M.H., Van Giersbergen, P.L.M., Jones, C.R.

Volltext

Characterization of an ETA receptor-like binding site on SK-N-MC cells von van Giersbergen, P.L.M., Huggins, J.

Volltext

Characterization of an ET A receptor-like binding site on SK-N-MC cells von van Giersbergen, P.L.M., Huggins, J.

Volltext

Preclinical profile of MDL 100 907, a potent and selective 5-HT2A antagonist in development for schizophrenia von Sorensen, S.M., Carr, A.A., van Giersbergen, P.L.M., Hitchcock, J.M., Kehne, J.H., Schmidt, C.J.

Volltext

The receptor binding profile of MDL 100,907 von van Giersbergen, P.L.M., Baron, B.M., Elands, J., Johnson, M.P., Sorensen, S.M.

Volltext

Preclinical profile of MDL 100 907, a potent and selective 5-HT 2A antagonist in development for schizophrenia von Sorensen, S.M., Carr, A.A., van Giersbergen, P.L.M., Hitchcock, J.M., Kehne, J.H., Schmidt, C.J.

Volltext

[Leu9 psi(CH2NH)Leu10]-neurokinin A (4-10) (MDL 28,564) distinguishes tissue tachykinin peptide NK2 receptors von Buck, S H, Harbeson, S L, Hassmann, 3rd, C F, Shatzer, S A, Rouissi, N, Nantel, F, van Giersbergen, P L

Volltext

Synthesis and biological evaluation of MDL 74,019DG, a centrally active M1 versus M2 selective muscarinic receptor antagonist von Van Hijfte, L., Zerr, V., Hibert, M., Marciniak, G., Moser, P., Moran, P., Richards, M.H., van Giersbergen, P.L.M.

Volltext

Synthesis and biological evaluation of MDL 74,019DG, a centrally active M 1 versus M 2 selective muscarinic receptor antagonist von Van Hijfte, L., Zerr, V., Hibert, M., Marciniak, G., Moser, P., Moran, P., Richards, M.H., van Giersbergen, P.L.M.

Volltext

Affinity of R 396, an NK-2 tachykinin receptor antagonist, for NK-2 receptors in preparations from different species von Maggi, C.A., Patacchini, R., Astolfi, M., Rovero, P., Giachetti, A., Van Giersbergen, P.L.M.

Volltext

Characterization of a tachykinin peptide NK sub 2 receptor transfected into murine fibroblast B82 cells von Van Giersbergen, P.L.M., Shatzer, S.A., Buck, S.H., Henderson, A.K., Lai, J., Yamamura, Henry, I., Nakanishi, Shigetada

Volltext

(Leu sup 9. phi. (CH sub 2 NH)Leu sup 10 )-neurokinin A(4-10) (MDL 28,564) distinguishes tissue tachykinin peptide NK sub 2 receptors von Buck, S.H., Harbeson, S.L., Hassmann, C.F. III, Shatzer, S.A., Rouissi, N., Nantel, F., van Giersbergen, P.L.M.

Volltext

[Leu 9ψ(CH 2NH)Leu 10]-Neurokinin A(4–10) (MDL 28, 564) distinguishes tissue tachykinin peptide NK 2 receptors von Buck, S.H., Harbeson, S.L., Hassmann, C.F., Shatzer, S.A., Rouissi, N., Nantel, F., van Giersbergen, P.L.M.

Volltext

β-endorphin and central control of arterial blood pressure during challenge of circulatory homeostasis von De Jong, W., Sandor, P., Cox-Van Put, J., Van Den Berg, M.H., Van Giersbergen, P.L.M.

Volltext

Involvement of brain opioid peptides in blood pressure regulation during controlled haemorrhagic hypotension von van Giersbergen, P.L.M., van den Berg, M.H., Cox-van Put, J., De Jong, W.

Volltext